AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca, in collaboration with Amgen, is ...

The BREATHE-3 trial hopes to determine the safety and impact of a novel bronchoscopic device on lung function in adults with ...

Patients with COPD are at increased risk for infections, making avoidance and effective treatments key in management.

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...

David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

Among adults with undiagnosed respiratory symptoms, those with undiagnosed COPD and asthma vs. preserved ratio impaired or ...

Phase 2 trial launched for verekitug in COPD, expanding treatment indications for severe respiratory conditions. Top data expected in 2026. Upstream Bio, Inc. has initiated a global Phase 2 clinical ...

This article supports the use of the chronic obstructive pulmonary disease (COPD) treatment ratio as a surrogate marker of COPD exacerbation risk for quality measurement purposes. Objectives: Despite ...

Most patients with chronic obstructive pulmonary disease (COPD) remain untreated after diagnosis, leading to frequent exacerbations. After COPD diagnosis, prompt and effective single or dual ...

In 2021, an estimated 14 million adults in the United States reported a diagnosis of chronic obstructive pulmonary disease (COPD), chronic bronchitis, or emphysema. If you’re not sure what the ...

Chronic obstructive pulmonary disease (COPD) and acute bronchitis both cause lung irritation and inflammation. They can trigger similar symptoms, including coughing, chest pain, and fatigue. Acute ...